



Alnylam Pharmaceuticals, Inc.
Investor Relations Department
300 Third Street
Cambridge, MA 02142
United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: ALNY ¹

| | |
|-------------------|--------------------------|
| Last Trade: | 85.21 |
| Trade Time: | 4:00 PM ET 06.23.2017 |
| Change: | 1.25 (1.489%) |
| Day Range | 82.13 - 85.33 |
| 52-Week Range | 31.38 - 86.92 |
| Volume | 773,700 |
| Market Cap. (\$M) | 7,795.863 |
| Shares Out (M) | 91.490 |

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics as genetic medicines, including programs as part of the company's "Alnylam 5x15™" product strategy. Alnylam's genetic medicine programs are RNAi therapeutics directed toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- 06.19.2017
[Alnylam CEO, John Maraganore, Named BIO Chair for 2017-2018 Term](#)
- 06.12.2017
[Alnylam Significantly Expands Patent Portfolio with New Allowances from United States Patent and Trademark Office](#)
- 06.07.2017
[Alnylam Expands Third Annual "Helping Hands" Community Service Day Globally to Benefit 18 Organizations](#)
- 05.31.2017
[FDA Grants Breakthrough Therapy Designation for Alnylam's Givosiran for the Prophylaxis of Attacks in Patients with Acute Hepatic Porphyria](#)
- 05.30.2017
[Alnylam to Webcast Presentation at Jefferies 2017 Healthcare Conference](#)

Events [\[View all \]](#)

There are no events to display at this time. Please check back later.

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

- 02.15.2017
[Annual Report \(10-K\)](#)
- 03.17.2017
[Definitive Proxy Statement](#)
- 05.05.2017
[Quarterly Report \(10-Q\)](#)
- 11.03.2016
[Quarterly Report \(10-Q\)](#)
- 08.04.2016
[Quarterly Report \(10-Q\)](#)